Pharmafile Logo
Pharmafocus logo
Advanced Search

multiple sclerosis

Showing 15 posts of 105 posts found.

FDA approves Biogen and Alkermes’ Vumerity for relapsing multiple sclerosis

October 30, 2019
Research and Development, Sales and Marketing Alkermes, Biogen, FDA, Vumerity, multiple sclerosis, pharma

The FDA has given the green light to Vumerity (diroximel fumarate), a novel oral fumarate developed by Biogen and Alkermes, …

News

Novartis announce robust Phase 3 trials for ofatumumab in MS

September 16, 2019
Research and Development, Sales and Marketing Aubagio, Novartis, multiple sclerosis

Novartis’ multiple sclerosis candidate has demonstrated strong results in its Phase 3 ASCLEPIOS trials meeting primary endpoints and slashing the …

News

Multi-study data confirms Ocrevus’ long-term efficacy in reducing disability progression in multiple sclerosis

September 13, 2019
Medical Communications, Research and Development ECTRIMS, Ocrevus, Roche, multiple sclerosis, pharma

Roche has taken the opportunity at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference in Stockholm …

News

Novartis’ Mayzent delays time wheelchair dependence by 4 years in secondary progressive multiple sclerosis

September 12, 2019
Research and Development ECTRIMS 2019, Mayzent, Novartis, multiple sclerosis, pharma

Novartis has taken the opportunity at the 2019 Congress of The European Committee for Treatment and Research in Multiple Sclerosis …

News
biogen_austria_238

Decade-long data support Biogen’s Tecfidera in relapsing multiple sclerosis

September 11, 2019
Research and Development Biogen, multiple sclerosis, pharma, tecfidera

Biogen has revealed new long-term data for Tecfidera (dimethyl fumarate), reinforcing the benefits of the therapy over a decade-long period …

News
sandoz

Sandoz acquires global commercialisation rights to Polpharma’s multiple sclerosis biosimilar

September 3, 2019
Manufacturing and Production, Sales and Marketing Polpharma, Sandoz, biosimilar, multiple sclerosis, pharma

Sandoz has revealed that it has sealed a deal with Polpharma Biologics to commercialise the latter’s proposed biosimilar version of …

News
novartis_outside_1

Novartis’ ofatumumab outclasses Sanofi’s Aubagio at Phase 3 in relapsing multiple sclerosis

September 3, 2019
Manufacturing and Production, Research and Development Arzerra, Genmab, Novartis, multiple sclerosis, pharma

New data from two Phase 3 studies have indicated that Novartis’ ofatumumab outperformed Sanofi Genzyme’s Aubagio (teriflunomide) in the treatment …

News
shutterstock_159488225

Genmab & Novartis’ ofatumumab tops Sanofi’s Aubagio in relapsing multiple sclerosis

August 30, 2019
Medical Communications, Research and Development Genmab, Novartis, multiple sclerosis, ofatumumab, pharma

Genmab and Novartis have revealed positive new data from two Phase 3 studies of its monthly subcutaneous formulation of ofatumumab …

News
shutterstock_212432119

Biogen & Alkermes’ multiple sclerosis drug proves “statistically superior” to Tecfidera at Phase 3

July 31, 2019
Research and Development Alkermes, Biogen, multiple sclerosis, pharma

Biogen and Alkermes have unveiled new Phase 3 data for diroximel fumarate, comparing the adequacy of the therapy to Biogen’s …

News

J&J’s ponesimod meets primary and secondary endpoints at Phase 3 in relapsing multiple sclerosis

July 26, 2019
Medical Communications, Research and Development Johnson & Johnson, multiple sclerosis, pharma, ponesimod

New Phase 3 data has been released on Johnson & Johnson’s selective sphingosine-1-phosphate receptor 1 (S1P1) modulator ponesimod, reporting that …

News
30805878966_19824f12fd_z

MRI scans can help predict MS patient’s long term prognosis, 15 year study shows

July 25, 2019
Research and Development CIS, MRI scans, MS, Prognosis, diagnosis, multiple sclerosis, pharma

MRI scans can predict MS patient’s long term prognosis when they are first diagnosed, according to new research. In a …

News
novartis_outside_1

A decade after US approval, Novartis’ Gilenya scores marketing authorisation in China for relapsing multiple sclerosis

July 19, 2019
Medical Communications, Sales and Marketing Novartis, gilenya, multiple sclerosis, pharma

Novartis has revealed that its disease modifying drug Gilenya (fingolimod) has secured approval in China for the treatment of relapsing …

News
biogen_austria_238

Biogen’s diroximel fumarate impresses at Phase 3 in relapsing multiple sclerosis

May 31, 2019
Medical Communications, Research and Development Biogen, diroximel fumarate, multiple sclerosis, pharma, relapsingg multiple sclerosis

New data for Biogen’s investigational therapy diroximel fumarate has been revealed at the Consortium of Multiple Sclerosis Centers (CMSC) in …

News
credit_-_daniel_leal-olivas-afp

Use of Genzyme’s MS drug Lemtrada restricted under ongoing EMA safety review

April 16, 2019
Manufacturing and Production, Sales and Marketing EMA, Genzyme, Lemtrada, multiple sclerosis, pharma

The EMA has launched a review into Genzyme’s multiple sclerosis drug Lemtrada (alemtuzumab) after reports emerged of treatment-related safety issues …

News
novartis_side_building

Novartis’ new MS drug to cost $88,000 a year

March 27, 2019
Research and Development, Sales and Marketing FDA, MS, Novartis, Novartis pharmaceuticals, multiple sclerosis

Paul Hudson, the CEO of Swiss firm Novartis Pharmaceuticals has said the company’s newly approved multiple sclerosis (MS) drug will …

News

Latest content

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024